Peter Evan Harwin insider trades: Crescent Biopharma (CBIO) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Peter reports to the SEC
and 7 more companies
Open-market buys and sales
15 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jul 16, 2026 | CBIO | ↑ Buy | 853,450 | $14.50 | $12.4M | By Fairmount Healthcare Fund II L.P. | Jul 20, 2026 (4d) |
| Jul 1, 2026 | ORKA | ↓ Sell | 3,553,410 | $84.43 | $300.0M | By Fairmount Healthcare Fund II L.P. | Jul 1, 2026 (0d) |
| Jun 23, 2026 | SYRE | ↓ Sell | 4,684,781 | $85.31 | $399.7M | By Fairmount Healthcare Fund II L.P. | Jun 23, 2026 (0d) |
| Mar 31, 2026 | ZBIO | ↑ Buy | 150,000 | $20.00 | $3.0M | By Fairmount Healthcare Fund II L.P. | Apr 1, 2026 (1d) |
| Jan 22, 2026 | APGE | ↓ Sell | 1,750,000 | $76.30 | $133.5M | By Fairmount Healthcare Fund II LP | Jan 22, 2026 (0d) |
| Dec 4, 2025 | CBIO | ↑ Buy | 1,360,000 | $13.41 | $18.2M | By Fairmount Healthcare Fund II L.P. | Dec 8, 2025 (4d) |
| Oct 7, 2025 | ZBIO | ↑ Buy | 316,219 | $19.00 | $6.0M | By Fairmount Healthcare Fund II L.P. | Oct 9, 2025 (2d) |
| Sep 16, 2024 | ZBIO | ↑ Buy | 300,000 | $17.00 | $5.1M | By Fairmount Healthcare Fund II LP | Sep 16, 2024 (0d) |
| Sep 29, 2023 | DNTH | ↑ Buy | 24,670 | $13.63 | $336K | Indirect | Oct 3, 2023 (4d) |
| Sep 26, 2023 | DNTH | ↑ Buy | 30,000 | $13.15 | $395K | Indirect | Sep 28, 2023 (2d) |
| Sep 19, 2023 | DNTH | ↑ Buy | 30,000 | $13.20 | $396K | Indirect | Sep 21, 2023 (2d) |
| Sep 13, 2023 | DNTH | ↑ Buy | 24,254 | $11.20 | $272K | Indirect | Sep 13, 2023 (0d) |
| Jul 13, 2023 | APGE | ↑ Buy | 1,992,734 | $17.00 | $33.9M | By Fairmount Healthcare Fund II LP | Jul 17, 2023 (4d) |
| Jul 13, 2023 | APGE | ↑ Buy | 892,529 | $17.00 | $15.2M | By Fairmount Healthcare Co-Invest II LP | Jul 17, 2023 (4d) |
| Jul 13, 2023 | APGE | ↑ Buy | 55,913 | $17.00 | $951K | By Fairmount Healthcare Fund LP | Jul 17, 2023 (4d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other CBIO insiders
Open-market trades in the last 12 months
About Peter Evan Harwin's insider trades
Peter Evan Harwin is a director at Crescent Biopharma (CBIO). Since Jul 13, 2023, Peter has reported 12 open-market purchases worth $96.1M and 3 sales worth $833.2M on SEC Form 4. In the last 12 months: 3 buys ($33.6M) and 3 sales ($833.2M).
Their filings also include grants and awards (32 filings), other transactions (5 filings), option exercises (4 filings), conversions (4 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every CBIO insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.